TIMP3 and glioma: Mechanistic studies have reported that exosome-derived MIF can enhance the sensitivity of drug-resistant glioma cells to TMZ via repressing the expression of metalloproteinase inhibitor 3 (TIMP3) and subsequently activating the PI3K/AKT signaling pathway [95].